Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

Julie A. Zorn
Bristol Myers Squibb
January 1, 2022
Sci Rep
https://pubmed.ncbi.nlm.nih.gov/35241687

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/35241687

Research summary

The study presents a novel immunocompetent mouse model with a strategically humanized CD3 epitope that enables in vivo evaluation of human CD3-targeting T-cell engagers. The model preserves normal T-cell development and supports effective testing of bispecific T-cell engagers, showing specific T-cell-mediated depletion of B cells in vivo.

Key outcome of the study

Maintains full immune competence while enabling preclinical testing of anti-human CD3 T-cell engagers; demonstrates potent B cell depletion with CD3/CD20 bispecific antibody.

Model

Humanized CD3ε epitope Knockin (hCD3E-epi) mouse model generated by genOway, with a human epitope sequence replacing the murine N-terminal CD3ε region, enabling recognition by clinical anti-hCD3 antibodies.

TARGET:
CD3E
Synonyms:
CD3 epsilon chain

Keywords

Immuno-oncology, T-cell engagers, CD3-targeting bispecific antibodies, Preclinical immunotherapy

Technical specifications

Humanized Knockin model, CD3ε epitope substitution, Immunocompetent background, T-cell engager evaluation

Related products

Catalogue product

genO‑panhCD3

genO‑panhCD3 (humanized ε, δ and γ chaines - hCD3edg) immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

genO‑hCD3ε

genO‑hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

Customized product

No items found.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe